WO2018088875A3 - 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 - Google Patents
외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 Download PDFInfo
- Publication number
- WO2018088875A3 WO2018088875A3 PCT/KR2017/012883 KR2017012883W WO2018088875A3 WO 2018088875 A3 WO2018088875 A3 WO 2018088875A3 KR 2017012883 W KR2017012883 W KR 2017012883W WO 2018088875 A3 WO2018088875 A3 WO 2018088875A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pbmc
- cells
- mitochondrium
- pharmaceutical composition
- same
- Prior art date
Links
- 210000000822 natural killer cell Anatomy 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 abstract 4
- 208000035473 Communicable disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000003013 cytotoxicity Effects 0.000 abstract 1
- 231100000135 cytotoxicity Toxicity 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000008105 immune reaction Effects 0.000 abstract 1
- 210000000987 immune system Anatomy 0.000 abstract 1
- 210000003470 mitochondria Anatomy 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4613—Natural-killer cells [NK or NK-T]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
Abstract
본 발명은 세포독성이 증가한 NK 세포 및 PBMC에 대한 것이다. 특히, 외래 미토콘드리아가 도입된 NK 세포 및 PBMC는 인체의 면역 체계를 강화하여 감염질환이나 암에 대한 치료효과를 증진시켜준다. 따라서, 상기 NK세포 및 PBMC를 포함하는 감염질환 및 암 예방 또는 치료용 조성물로 사용될 수 있다. 특히, 상기 NK 세포 및 PBMC가 자가 유래의 세포일 경우 면역반응을 유발하지 않아 안정성이 확보되는 바 상업적으로 활용가능성이 높을 것으로 기대된다.
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201780070481.5A CN109983120A (zh) | 2016-11-14 | 2017-11-14 | 含有外源线粒体的天然杀伤细胞和含有其的药物组合物 |
RU2019118070A RU2777371C2 (ru) | 2016-11-14 | 2017-11-14 | Клетка-естественный киллер, содержащая экзогенную митохондрию, и фармацевтическая композиция, включающая такую клетку |
EP17869358.6A EP3540048A4 (en) | 2016-11-14 | 2017-11-14 | NATURAL KILLER CELLS WITH EXOGENIC MITOCHONDRIUM AND PHARMACEUTICAL COMPOSITION THEREFOR |
JP2019525738A JP7074358B2 (ja) | 2016-11-14 | 2017-11-14 | 外因性ミトコンドリアを含むナチュラルキラー細胞および同細胞を含む医薬組成物 |
US16/349,310 US11278569B2 (en) | 2016-11-14 | 2017-11-14 | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
US17/483,193 US20220000930A1 (en) | 2016-11-14 | 2021-09-23 | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20160151411 | 2016-11-14 | ||
KR10-2016-0151411 | 2016-11-14 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/349,310 A-371-Of-International US11278569B2 (en) | 2016-11-14 | 2017-11-14 | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
US17/483,193 Continuation US20220000930A1 (en) | 2016-11-14 | 2021-09-23 | Natural killer cell containing exogenous mitochondrium and pharmaceutical composition comprising same |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2018088875A2 WO2018088875A2 (ko) | 2018-05-17 |
WO2018088875A3 true WO2018088875A3 (ko) | 2018-08-09 |
Family
ID=61977886
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2017/012883 WO2018088875A2 (ko) | 2016-11-14 | 2017-11-14 | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 |
Country Status (7)
Country | Link |
---|---|
US (2) | US11278569B2 (ko) |
EP (1) | EP3540048A4 (ko) |
JP (1) | JP7074358B2 (ko) |
KR (2) | KR101846464B1 (ko) |
CN (1) | CN109983120A (ko) |
RU (1) | RU2021134402A (ko) |
WO (1) | WO2018088875A2 (ko) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200071338A (ko) | 2018-12-11 | 2020-06-19 | 주식회사 스마트셀랩 | Nk 세포 활성 조절을 통한 비만의 예방 또는 치료 방법 |
WO2021004477A1 (zh) * | 2019-07-09 | 2021-01-14 | 唐凌峰 | 一种基于线粒体的药物递送系统及其用途 |
US20210309967A1 (en) * | 2020-04-03 | 2021-10-07 | Cellvie Inc. | Enhancement of adoptive cell transfer |
KR102290596B1 (ko) | 2020-09-10 | 2021-08-19 | 주식회사 파이안바이오테크놀로지 | 분리된 미토콘드리아를 포함하는 주사용 조성물 및 이의 용도 |
KR102273163B1 (ko) | 2020-09-10 | 2021-07-05 | 주식회사 파이안바이오테크놀로지 | 혈소판 유래 미토콘드리아의 수득 방법 및 이의 용도 |
CA3233989A1 (en) * | 2021-10-06 | 2023-04-13 | Nina DUMAUTHIOZ | Enhancing adoptive cell transfer by promoting a superior population of adaptive immune cells |
CN114699430A (zh) * | 2022-04-12 | 2022-07-05 | 重庆理工大学 | 线粒体及其在胰腺炎中的应用和应用方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130034527A1 (en) * | 2010-10-28 | 2013-02-07 | Searete Llc | Mitochondrial enhancement of cells |
KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
WO2015067089A1 (zh) * | 2013-11-08 | 2015-05-14 | 中国科学院广州生物医药与健康研究院 | 外源线粒体导入到哺乳动物细胞中的方法 |
WO2016008937A1 (en) * | 2014-07-16 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the intercellular transfer of isolated mitochondria in recipient cells |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2015526088A (ja) | 2012-08-13 | 2015-09-10 | アントフロゲネシス コーポレーション | ナチュラルキラー細胞及びその使用 |
CA2977341A1 (en) | 2015-02-26 | 2016-09-01 | Minovia Therapeutics Ltd. | Mammalian cells enriched with functional mitochondria |
-
2017
- 2017-11-14 EP EP17869358.6A patent/EP3540048A4/en active Pending
- 2017-11-14 JP JP2019525738A patent/JP7074358B2/ja active Active
- 2017-11-14 CN CN201780070481.5A patent/CN109983120A/zh active Pending
- 2017-11-14 US US16/349,310 patent/US11278569B2/en active Active
- 2017-11-14 RU RU2021134402A patent/RU2021134402A/ru unknown
- 2017-11-14 WO PCT/KR2017/012883 patent/WO2018088875A2/ko unknown
- 2017-11-14 KR KR1020170151503A patent/KR101846464B1/ko active IP Right Grant
-
2018
- 2018-03-22 KR KR1020180033127A patent/KR20180054523A/ko not_active Application Discontinuation
-
2021
- 2021-09-23 US US17/483,193 patent/US20220000930A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20130034527A1 (en) * | 2010-10-28 | 2013-02-07 | Searete Llc | Mitochondrial enhancement of cells |
KR20140123503A (ko) * | 2011-12-22 | 2014-10-22 | 재단법인 목암생명공학연구소 | 자연살해세포의 제조방법, 이러한 방법에 의해 제조된 자연살해세포 및 이를 포함하는 종양 및 감염성 질환 치료용 조성물 |
WO2015067089A1 (zh) * | 2013-11-08 | 2015-05-14 | 中国科学院广州生物医药与健康研究院 | 外源线粒体导入到哺乳动物细胞中的方法 |
WO2016008937A1 (en) * | 2014-07-16 | 2016-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the intercellular transfer of isolated mitochondria in recipient cells |
Non-Patent Citations (1)
Title |
---|
KITANI, T. ET AL.: "Internalization of Isolated Functional Mitochondria: Involvement of Macropinocytosis", JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, vol. 18, no. 8, June 2014 (2014-06-01), pages 1694 - 1703, XP055135790 * |
Also Published As
Publication number | Publication date |
---|---|
CN109983120A (zh) | 2019-07-05 |
US20220000930A1 (en) | 2022-01-06 |
EP3540048A4 (en) | 2020-06-24 |
US20190269731A1 (en) | 2019-09-05 |
KR20180054523A (ko) | 2018-05-24 |
RU2019118070A3 (ko) | 2021-08-13 |
RU2019118070A (ru) | 2020-12-14 |
WO2018088875A2 (ko) | 2018-05-17 |
RU2021134402A (ru) | 2022-01-14 |
EP3540048A2 (en) | 2019-09-18 |
JP7074358B2 (ja) | 2022-05-24 |
KR101846464B1 (ko) | 2018-04-09 |
US11278569B2 (en) | 2022-03-22 |
JP2019534029A (ja) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2018088875A3 (ko) | 외래 미토콘드리아를 포함하는 자연살해세포 및 이를 포함하는 약학적 조성물 | |
CA2956871C (en) | Compounds active towards bromodomains | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
EP4230627A3 (en) | Inhibitors of the menin-mll interaction | |
PH12017501342A1 (en) | Glycan therapeutics and related methods thereof | |
EP4219713A3 (en) | Products and compositions | |
MX2022009187A (es) | Antifolatos poliglutamados alfa y gamma-d y sus usos. | |
WO2016172657A3 (en) | Glycan therapeutics and methods of treatment | |
MX2019000588A (es) | Moduladores de la somatostatina y usos de los mismos. | |
MX2017007641A (es) | Conjugados de anticuerpo-farmaco con inhibidores de bcl-xl permeables en las celulas. | |
MX2017014082A (es) | Nuevas proteinas especificas para cd137. | |
MX2021013766A (es) | Restos de separacion y metodos de uso de los mismos. | |
SG10201808104RA (en) | Cenicriviroc for the treatment of fibrosis | |
PH12014501815A1 (en) | Purinone compounds as kinase inhibitors | |
BR112016024352A2 (pt) | ?cepa de listeria recombinante, listeria recombinante, composição farmacêutica, e, métodos de induzir uma resposta imune contra um tumor ou um câncer em um indivíduo humano e de listeria? | |
EP4310500A3 (en) | Methods and compositons for the activation of gamma-delta t-cells | |
TW201613919A (en) | Inhibitors of Bruton's tyrosine kinase | |
BR112015015898A2 (pt) | composição farmacêutica de solução sólida | |
MX2019010949A (es) | Moduladores de somatostatina y usos de los mismos. | |
MX2015016741A (es) | Inhibidores de pi3 cinasa delta y gama selectivos duales. | |
AR104598A1 (es) | Métodos para tratar trastornos linfoproliferativos asociados al virus de epstein-barr por terapia con células t | |
MX2021010041A (es) | Composiciones farmaceuticas que comprenden inhibidores de la proteina quinasa akt. | |
MX357284B (es) | Compuestos de quinona para tratar enfermedades mediadas por ape1. | |
MX2017006437A (es) | Compuestos espiroisoquinolin-1,4'-piperidinicos con actividad multimodal contra el dolor. | |
MX2019002699A (es) | Terapia genica para pacientes con anemia de fanconi. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 17869358 Country of ref document: EP Kind code of ref document: A2 |
|
ENP | Entry into the national phase |
Ref document number: 2019525738 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2017869358 Country of ref document: EP Effective date: 20190614 |